secwatch.observer — SEC 8-K summary
======================================

Issuer:     IRIDEX CORP (IRIX)
CIK:        0001006045
Form:       8-K
Filed at:   2023-11-14T23:59:59+00:00
Accession:  0000950170-23-063762
Event type: other_material
Sentiment:  negative
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Iridex Q3 revenue $12.9M (-12% YoY); five MACs restrict glaucoma reimbursement; guidance withdrawn
--------------------------------------------------------------------------------

- Q3 revenue $12.9M, down 12% YoY; net loss $1.8M ($0.11/share) flat vs prior year.
- Cyclo G6 revenue $3.0M (-12% YoY); probes up 3% but system sales fell to 27 units (vs 54 prior year).
- Five U.S. MACs issued LCDs restricting cyclophotocoagulation reimbursement (effective Dec 24); Iridex appealing and challenging the criteria.
- Guidance withdrawn for FY2023 due to uncertainty from LCDs impacting Cyclo G6 system and probe sales.
- Strategic review announced in August; Piper Sandler engaged as financial advisor to explore alternatives.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1006045/000095017023063762/0000950170-23-063762-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1006045/000095017023063762/irix-20231114.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-063762

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer